Clinical Trial Update: Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Liver Function and Healthy Participants [Phase 1]

View source ↗

Summary

Phase 1 study of Pirtobrutinib in healthy participants and those with hepatic impairment completed, with results posted; the data inform pharmacokinetics and sa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Insufficiency
• Liver Disease

Drugs mentioned

• Pirtobrutinib (pirtobrutinib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Healthy, Hepatic Insufficiency | Phase 1 | Status: COMPLETED | Results posted: 2025-01-09